Share-based Payment Arrangement, Expense of RAPT Therapeutics, Inc. from 30 Sep 2018 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
RAPT Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2018 to 30 Sep 2025.
  • RAPT Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $5,029,000, a 10% increase year-over-year.
  • RAPT Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $18,803,000, a 4.9% decline year-over-year.
  • RAPT Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $19,935,000, a 17% increase from 2023.
  • RAPT Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $17,091,000, a 52% increase from 2022.
  • RAPT Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $11,264,000, a 13% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

RAPT Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $18,803,000 $5,029,000 +$465,000 +10% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $18,338,000 $4,537,000 -$847,000 -16% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $19,185,000 $4,648,000 -$750,000 -14% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $19,935,000 $4,589,000 +$160,000 +3.6% 01 Oct 2024 31 Dec 2024 10-K 06 Mar 2025 2024 FY
Q3 2024 $19,775,000 $4,564,000 +$235,000 +5.4% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $19,540,000 $5,384,000 +$1,145,000 +27% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $18,395,000 $5,398,000 +$1,304,000 +32% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $17,091,000 $4,429,000 +$1,404,000 +46% 01 Oct 2023 31 Dec 2023 10-K 06 Mar 2025 2024 FY
Q3 2023 $15,687,000 $4,329,000 +$1,464,000 +51% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $14,223,000 $4,239,000 +$1,567,000 +59% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $12,656,000 $4,094,000 +$1,392,000 +52% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $11,264,000 $3,025,000 +$653,000 +28% 01 Oct 2022 31 Dec 2022 10-K 07 Mar 2024 2023 FY
Q3 2022 $10,611,000 $2,865,000 +$860,000 +43% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $9,751,000 $2,672,000 -$216,000 -7.5% 01 Apr 2022 30 Jun 2022 10-Q 11 Aug 2023 2023 Q2
Q1 2022 $9,967,000 $2,702,000 +$15,000 +0.56% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $9,952,000 $2,372,000 -$186,000 -7.3% 01 Oct 2021 31 Dec 2021 10-K 14 Mar 2023 2022 FY
Q3 2021 $10,138,000 $2,005,000 $0 0% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $10,138,000 $2,888,000 +$853,000 +42% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $9,285,000 $2,687,000 +$599,000 +29% 01 Jan 2021 31 Mar 2021 10-Q 11 May 2022 2022 Q1
Q4 2020 $8,686,000 $2,558,000 +$1,662,000 +185% 01 Oct 2020 31 Dec 2020 10-K 10 Mar 2022 2021 FY
Q3 2020 $7,024,000 $2,005,000 +$1,574,000 +365% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $5,450,000 $2,035,000 +$1,688,000 +486% 01 Apr 2020 30 Jun 2020 10-Q 11 Aug 2021 2021 Q2
Q1 2020 $3,762,000 $2,088,000 +$1,711,000 +454% 01 Jan 2020 31 Mar 2020 10-Q 11 May 2021 2021 Q1
Q4 2019 $2,051,000 $896,000 01 Oct 2019 31 Dec 2019 10-K 11 Mar 2021 2020 FY
Q3 2019 $431,000 +$136,000 +46% 01 Jul 2019 30 Sep 2019 10-Q 16 Nov 2020 2020 Q3
Q2 2019 $347,000 01 Apr 2019 30 Jun 2019 10-Q 13 Aug 2020 2020 Q2
Q1 2019 $377,000 01 Jan 2019 31 Mar 2019 10-Q 14 May 2020 2020 Q1
Q3 2018 $295,000 01 Jul 2018 30 Sep 2018 10-Q 11 Dec 2019 2019 Q3

RAPT Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $19,935,000 +$2,844,000 +17% 01 Jan 2024 31 Dec 2024 10-K 06 Mar 2025 2024 FY
2023 $17,091,000 +$5,827,000 +52% 01 Jan 2023 31 Dec 2023 10-K 06 Mar 2025 2024 FY
2022 $11,264,000 +$1,312,000 +13% 01 Jan 2022 31 Dec 2022 10-K 07 Mar 2024 2023 FY
2021 $9,952,000 +$1,266,000 +15% 01 Jan 2021 31 Dec 2021 10-K 14 Mar 2023 2022 FY
2020 $8,686,000 +$6,635,000 +324% 01 Jan 2020 31 Dec 2020 10-K 10 Mar 2022 2021 FY
2019 $2,051,000 +$881,000 +75% 01 Jan 2019 31 Dec 2019 10-K 11 Mar 2021 2020 FY
2018 $1,170,000 01 Jan 2018 31 Dec 2018 10-K 30 Mar 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.